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A B S T R A C T
This multicentre prospective study was conducted to investigate whether the level of the soluble form of
urokinase-type plasminogen activator receptor (suPAR) is elevated during pneumococcal bacteraemia
and is of predictive value in the early stage of the disease. Plasma levels of suPAR were increased
significantly (median 5.5; range 2.4–21.0 ng ⁄mL) in 141 patients with pneumococcal bacteraemia,
compared to 31 healthy controls (median 2.6, range 1.5–4.0 ng ⁄mL, p 0.001). Furthermore, suPAR levels
were elevated significantly in patients who died from the infection (n ¼ 24) compared to survivors
(n ¼ 117; p < 0.001). No correlation was found between suPAR levels and C-reactive protein. In
univariate logistic regression analysis, hypotension, renal failure, cerebral symptoms and high serum
concentrations of protein YKL-40 and suPAR were associated significantly with mortality (p < 0.05). In
multivariate analysis, only suPAR remained a significant predictor of death (mortality rate of 13 for
suPAR levels of > 10 ng ⁄mL; 95% CI: 1.1–158). The increase in suPAR levels may reflect increased
expression by vascular or inflammatory cells in the setting of pneumococcal sepsis. This plasma protein
may be used to identify patients who are severely ill with pneumococcal bacteraemia.
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I N T R O D U C T I O N
Streptococcus pneumoniae is the primary agent of
community-acquired pneumonia [1] and is also
associated with bacteraemia [2]. The annual inci-
dence of pneumonia is estimated at 1–12 ⁄ 1000
population in developed countries [3]. Pneumo-
coccal bacteraemia ranges from 9–18 ⁄ 100 000 ⁄year
[4,5], with 17–36% mortality and the highest
mortality amongst the elderly [6].
Urokinase-type plasminogen activator receptor
(uPAR ⁄CD87) is expressed on different cell
types, including neutrophils, lymphocytes, macr-
ophages, endothelial and malignant cells.
uPAR and its ligand, urokinase-type plasminogen
activator (uPA), are involved in numerous biolo-
gical functions. In the pathogenesis of cancer,
uPA and uPAR play a key role in tissue invasion
by converting plasminogen into plasmin, leading
to the degradation of extracellular matrix [7].
uPAR is able to bind b-integrins [8] promoting the
migration of leukocytes [9]. uPAR can be cleaved
from the cell surface by a number of proteases,
such as chymotrypsin [10], phospholipase C [11]
and uPA [12], to yield a soluble form of the
receptor, suPAR. Proteolytic cleavage of uPAR
from the cell surface can release a chemotactic
active form of suPAR [13,14].
Recently, a strong correlation between the
advanced disease state of HIV-1 infection and
elevated suPAR levels was reported, suggesting
the use of suPAR as a prognostic marker [15]. The
reason for the strong prognostic value of suPAR
in HIV infection is unknown, but binding of uPA
to uPAR inhibits late stages of the HIV-1 life-cycle
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in vitro [16,17]. suPAR has also been shown to be
elevated and of prognostic value in patients with
active pulmonary tuberculosis, and to be reduced
following therapy [18].
The possible role of suPAR and uPA in
immune responses to infectious diseases remains
to be investigated. Gene knockout mice lacking
uPAR have shown reduced pulmonary neutro-
phil recruitment and increased mortality to infec-
tion with S. pneumoniae compared to wild-type
mice [19]. Up-regulation of uPAR on monocytes
and leukocytes has been shown in experimental
lipopolysaccharide endotoxaemia [20]. Lipotei-
choic acid from Streptococcus pyogenes, as well as
Borrelia burgdorferi surface proteins, facilitates
monocyte uPAR and suPAR up-regulation in vitro
[21].
Elevated serum levels of protein YKL-40, a
lectin secreted from leukocytes, have been des-
cribed during pneumonia [22], and Kronborg
et al. [23] have shown that YKL-40 is an inde-
pendent prognostic factor in pneumococcal bac-
teraemic patients. To our knowledge, besides
YKL-40, only the APACHE II score has prognostic
value for pneumonia, although this is limited [24].
The present study investigated whether the
plasma suPAR level is elevated and associated
with outcome in patients with S. pneumoniae
bacteraemia.
P A T I E N T S A N D M E T H O D S
Patients
Between October 1999 and June 2001, adults with S. pneumoniae
bacteraemia admitted to one of five university hospitals
(Aalborg, Aarhus, Odense, Hvidovre or Rigshospitalet) in
Denmark were studied. Blood samples were taken on admission
and clinical data were collected prospectively as described
previously [25]. In total, 141 patients (77 female and 64 male)
were included in the study (mean age 64 years; range
20–99 years). Most (66%) of the patients had an underlying
illness: alcoholism (n ¼ 21), chronic obstructive lung disease
(n ¼ 18), diabetes (n ¼ 13), malignancy (n ¼ 19), congestive
cardiac disease (n ¼ 7), HIV (n ¼ 1) or others (n ¼ 13). Pneu-
monia was the commonest type of infection (n ¼ 116). Twenty-
four patients died in hospital (case fatality rate of 17%); the cause
of death was not determined systematically, but pneumococcal
bacteraemia was considered to be the primary cause of death.
Baseline characteristics of the patients are given in Table 1.
All patients received appropriate antibiotic treatment, either
from admission or from the point when the blood culture
became positive (i.e., within the first 24 h). The control group
consisted of 31 healthy individuals (laboratory workers; 27 male
and four female; median age 49 years; range 31–63 years). The
study was approved by the local Ethical Committees.
ELISA
Maxisorb plates (Nunc, Roskilde, Denmark) were coated and
incubated overnight at 4 C with 100 lL of murine monoclonal
anti-suPAR antibody 2 lg ⁄mL against human suPAR (kindly
provided by Dr G. Hoyer-Hansen, Finsen Laboratory, Copen-
hagen, Denmark), diluted in coating buffer (15.1 mM Na2CO3,
35.7 mM NaHC3, pH 9.6). Plates were washed with wash
buffer (phosphate buffered saline (PBS) containing Tween 20
0.1% v ⁄v) and blocked with SuperBlock (Pierce Chemicals,
Dallas, TX, USA) diluted 1:1 in PBS. Plasma samples diluted in
dilution buffer (7.3 mM KH2PO4, 50.7 mM Na2HPO4, 0.1 M
NaCl, phenol red 0.5% w ⁄w, pH 7.4) were added and the
plates were incubated overnight at 4 C. Bound suPAR was
detected using 100 lL of rabbit anti-human suPAR polyclonal
antibody 1.0 lg ⁄mL (kindly provided by Dr G. Hoyer-Hansen)
and mouse anti-rabbit polyclonal antibody conjugated with
alkaline phosphatase (Sigma, St. Louis, MO, USA), diluted
1:2000. Each step was preceded by six washes with wash
buffer, the antibodies were diluted in dilution buffer, and the
plates were incubated for 1 h at 37 C. Substrate (one tablet of
p-nitrophenyl phosphate (Sigma) dissolved in 12 mL of 0.1 M
Tris, 0.1 M NaCl, 5 mM MgCl2, pH 9.5) was added to the
wells and incubated at room temperature for 30 min. Reactions
Table 1. Age and sex distribution of the 141 patients
included in the study and prognostic factors in Streptococcus
pneumoniae bacteraemia. The table shows the mortality rate
(MR) predicted by the different prognostic factors. All
factors in the univariate logistic regression analysis were
significant (p < 0.05). In the multivariate analysis, only
suPAR levels above 10 ng ⁄mL remained significant
Characteristic n (died) % mortality (%)
Age, years
18–60 54 (6) 39 11
61–75 50 (11) 35 22
> 75 37 (7) 26 19
Male 64 (13) 45 21
Univariate analysis n MR 95% CI p
Treatment of hypotensiona 19 (6) 3.0 1.0–9.0 0.05
Cerebral symptomsa,b 41 (11) 2.9 1.1–7.4 0.03
Haemodialysisa 11 (6) 8.4 2.3–30.7 0.002
Alcoholism 21 (7) 3.0 1.0–8.5 0.04
YKL-40 level (ng ⁄mL)
0–200 29 (2) 1.0 – –
201–500 30 (3) 1.5 0.2–9.0 0.6
‡ 501 30 (14) 11.8 2.4–58.8 0.003
suPAR level (ng ⁄mL)
0–5 64 (4) 1.0 – –
5.1–10 55 (9) 3.0 0.8–10.1 0.08
‡ 10.1 19 (11) 20.6 5.3–80 0.0001
Multivariate analysis n MR 95% CI p
Treatment of hypotensiona 19 (6) 0.1 0–2 0.1
Cerebral symptomsa,b 41 (11) 3.7 0.8–17.1 0.09
Haemodialysisa 11 (6) 6.4 0.3–118 0.2
Alcoholism 21 (7) 0.8 0.2–6.2 0.8
YKL-40 level (ng ⁄mL)
0–200 29 (2) 1.0 – –
201–500 30 (3) 0.8 0.08–7.9 0.8
‡ 501 30 (14) 3.9 0.4–35 0.2
suPAR level (ng ⁄mL)
0–5 64 (4) 1.0 – –
5.1–10 55 (9) 2.2 0.3–16.8 0.4
‡ 10.1 19 (11) 13.0 1.1–158 0.04
aData were only available for 139 patients.
bCerebral symptoms were defined as unconsciousness or severe confusion at
admission.
CI, Confidence Interval.
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were stopped by adding 50 lL of 1 M NaOH ⁄well, and the
absorbance was read at 405 nm. All ELISA measurements
were carried out in duplicate. YKL-40 levels were measured by
ELISA as described previously [23].
Statistics
Comparisons between groups were made with the Mann–
Whitney U-test. When comparing suPAR levels in patients
with underlying diseases, patients with multiple foci were
excluded from the analysis. The use of suPAR as a prognostic
marker was analysed using logistic regression analysis.
p-values <0.05 were considered significant. All analyses were
carried out using SPSS software (SPSS, Chicago, IL, USA).
R E S U L T S
The plasma level of suPAR was measurable in all
141 samples, with a median value of 5.5 ng ⁄mL
(range 2.4–21.0 ng ⁄mL). The median level of
suPAR in the control group was 2.6 ng ⁄mL (range
1.5–4.0 ng ⁄mL). The suPAR levels in the pneu-
mococcal bacteraemic patients were significantly
higher than in the healthy controls (Fig. 1a;
p 0.001). The suPAR levels in patients with
pneumonia (n ¼ 113) as the single underlying
disease were significantly higher (median 5.6;
range 2.7-21.0 ng ⁄mL) than in patients with otitis
media or meningitis as the single underlying
disease (n ¼ 22; median 4.1; range 2.1–15.1 ng ⁄mL;
p 0.032); patients with multiple sites of infection
were excluded. There was no correlation between
suPAR levels and age (r ) 0.123; p 0.15).
Significantly higher suPAR levels were meas-
ured in the patients who died (n ¼ 24) compared
to the survivors (n ¼ 117) (Fig. 1b; p 0.0001). In
the former group, 19 (79%) had suPAR levels
above the median of 5.5 ng ⁄mL. Fig. 2 shows the
sensitivity and specificity of suPAR at different
cut-off values.
The clinical parameters of prognostic import-
ance in terms of death caused by the infection were
cerebral symptoms (confusion, unconsciousness)
at time of admission (p 0.03), hypotension (p 0.047)
and kidney failure (p 0.002) (Table 1) [25]. The
suPAR level was elevated significantly in patients
with hypotension (p 0.0001) and renal failure
(p 0.0001). The suPAR level was also elevated in
the group of chronic alcohol abusers (p 0.0001).
Underlying diseases were not associated signifi-
cantly with a fatal outcome of pneumococcal
bacteraemia, except for alcoholism (p 0.04).
C-reactive protein (CRP) was quantified in
most (n ¼ 131) of the patients. There was no
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Fig. 1. Box plots based on the median, quartiles and
extreme values of plasma suPAR levels. (a) Control group
(median ¼ 2.6 ng ⁄mL) and pneumococcal bacteraemic
patients (median ¼ 5.5 ng ⁄mL). The suPAR level was
elevated significantly in patients compared to controls
(p 0.001). (b) Patients surviving the infection (med-
ian ¼ 5.0 ng ⁄mL) and patients dying from the infection
(median ¼ 9.4 ng ⁄mL). The increased level of suPAR in
the group of fatilities was statistically significant (p 0.0001).
The boxes represent the interquartile range that contains
50% of the values, with the highest and lowest values
indicated, excluding outliers and extremes. Circles (o)
represent outliers (1.5 and 3 box-lengths) and stars (*)
represent extremes (values more than three box lengths).
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correlation between suPAR levels and CRP levels
(r ) 0.004; p 0.96). High CRP levels were not
prognostic of death. Neutrophils showed a weak
but significant negative correlation to suPAR
levels (Spearman rank correlation coefficient:
– 0.237; p 0.006). When comparing suPAR levels
with YKL-40 levels (n ¼ 89), a strong correlation
was identified between suPAR and YKL-40
(Spearman rank correlation coefficient: 0.70;
p 0.0001).
In a logistic multivariate regression analysis
(Table 1) that included all parameters found to be
significant in univariate analysis (cerebral symp-
toms, mechanical ventilation, treatment of hypo-
tension, renal failure, alcohol abuse and YKL-40),
only the suPAR level remained associated signi-
ficantly with death. The increase in mortality rate
was 1.31 ⁄ng suPAR (95%CI: 1.10–1.57; p 0.0064).
The suPAR levels ranged from 2.4 to 21.0 ng ⁄mL.
Patients with plasma suPAR levels of > 10 ng ⁄mL
had a mortality rate of 13 (p 0.04 compared to
patients with suPAR levels between 0 and
5 ng ⁄mL).
D I S C U S S I O N
Studies have shown that uPAR knock-out mice
have decreased neutrophil recruitment to the lung
and increased mortality to pneumococcal pneu-
monia compared to wild-type mice [19]. Further-
more, the presence of uPAR is crucial for
leukocyte adherence to the endothelium [26].
uPAR regulates cell migration; it can bind to
b-integrins and may mediate cell–to–cell
interaction and induce signal transduction [27].
However, cell migration in pneumococcal pneu-
monia is independent of binding b2 integrins [19],
suggesting the involvement of other mechanisms
in uPAR-mediated migration. uPAR knock-out
mice have shown similar results with respect to
neutrophil recruitment during Pseudomonas aeru-
ginosa infection, which is a b2 integrin-dependent
migration [28].
Mice lacking the uPAR ligand, uPA, have a
possible increased immune response to S. pneu-
moniae [19]. Despite this, the absence of uPA in
both Cryptococcus neoformans [29] and Pneumocys-
tis carinii [30] infections in mice caused an
impaired immune response. Lymphocyte recruit-
ment to the lung was diminished in uPAR
deficient mice, while recruitment was unaffected
in uPA knock-out mice [31]. These observations
suggest that uPAR is needed for neutrophil and
lymphocyte recruitment, but that the mechanism
is, at least partly, independent of proteolytic ability.
The present study demonstrated that suPAR
levels are highly elevated and of prognostic value
in patients with pneumococcal bacteraemia.
Elevated suPAR levels have been shown previ-
ously to be of prognostic value for patients with
various forms of malignant diseases [32–36], as
well as with HIV-1 infection [15], urinary tract
infection [37], tuberculosis infection [18], and
bacterial meningitis [38]. Similarly, increased
suPAR levels in the present study were a strong
predictor of mortality. Other factors (see Results)
were all of prognostic value, but only elevated
suPAR levels were an independent predictor of
mortality in multivariate logistic regression ana-
lysis. The strength of suPAR as a prognostic tool
is illustrated in Fig. 2. With a cut-off value of
10 ng ⁄mL, the specificity was 0.95, sensitivity
was 0.38, the negative predictive value (NPV) was
0.88, and the positive predictive value (PPV) was
0.60. The high specificity and NPV should assist
in identifying the large proportion of patients
with a good prognosis. Hence, plasma suPAR
levels could be used as a novel prognostic marker
to identify high-risk patients.
It is difficult to compare suPAR values from
different studies because of interassay variations
and differences in the clinical conditions of the
patients included. However, the very high eleva-
tions of suPAR levels found in the present study
were similar to those found in urosepsis patients
infected primarily by Escherichia coli [37], and
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Fig. 2. Diagram showing sensitivity(d) and specificity (j)
for each suPAR value. With a cut-off value of 10 ng ⁄mL,
the specificity was 0.95 and the sensitivity was 0.38.
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eight patients with bacterial meningitis infected
by S. pneumoniae [38].
Evidence for the origin of plasma suPAR
remains scarce. However, it is known that uPAR
consists of three domains, and that proteolytic
cleavage between domains 1 (D1) and 2 + 3 (D2D3)
yields the active chemotactic domain D2D3 [13,14].
Proteolytic cleavage is mediated by both its
own ligand, uPA [12], and by different proteases,
e.g., chymotrypsin. The present study used a
catching antibody of monoclonal anti-suPAR
directed against domain 3 in the ELISA, thus
detecting both intact suPAR and the chemotactic
domain D2D3. During pneumococcal pneumonia,
cytokines and different chemo-attractants are
released, and increased mortality is associated
with a high pulmonary interleukin-6 level [39].
Florquin et al. [37] found elevated suPAR levels in
urosepsis patients, and suggested that suPAR was
produced in the infected organ because of higher
urine-to-plasma ratios and up-regulation of uPAR
in the renal tubuli during infection. The elevated
plasma suPAR levels seen in pneumococcal bac-
teraemia may be caused by increased secretion
from leukocytes. Another source could be release
of suPAR from vascular cells stimulated by cytok-
ines, as shown by Chavakis et al. [40].
Elevated plasma suPAR levels have also been
reported from a group (n ¼ 13) of intensive care
unit sepsis patients [41], suggesting that secretion
of suPAR is increased during acute inflammation.
In this study, suPAR and CRP levels were
compared and no correlation was identified. This
finding was supported by Slot et al. [42], who
found no correlation between suPAR and CRP
in patients with rheumatic diseases. However,
suPAR levels are highly elevated in both E. coli
sepsis and pneumococcal bacteraemia, suggesting
an immunological response to severe infections.
The serum level of YKL-40, a matrix protein
from neutrophils, has also been shown to be
elevated during pneumonia and to decrease in
response to therapy [22]. Patients from the present
cohort also had elevated serum YKL-40 levels that
were found to be an independent prognostic
factor [23]. A positive correlation between suPAR
and YKL-40 levels was identified. In the multiva-
riate analysis, YKL-40 levels > 500 ng ⁄mL, cereb-
ral symptoms and haemodialysis were associated
with an elevated mortality rate, but the associa-
tions were not significant. There was an inverse
correlation between the number of neutrophils
and suPAR levels, which may be explained by
leukocyte depletion in severely ill patients.
Interestingly, lipopolysaccharide has been
shown to up-regulate uPAR in monocytes and
leukocytes, both in vitro and in vivo in healthy
volunteers [20]. Surface proteins from S. pyogenes,
Salmonella typhimurium and B. burgdorferi are also
able to induce up-regulation of uPAR in mono-
cytes and elevate suPAR in vitro. Thus, increased
uPAR levels may be an immunological mechan-
ism leading to increased cell migration in re-
sponse to bacterial infections. As high suPAR
levels are correlated with high uPAR levels [34],
suPAR levels may be correlated with bacterial
load and severity of the infection. Patients with
pneumonia as the underlying disease had signi-
ficantly higher suPAR levels compared to patients
with other underlying diseases, despite equal
mortality rates between these two groups. This
difference might be explained by greater inva-
siveness of the infection in pneumonic patients,
leading to a greater suPAR response. It remains to
be determined whether suPAR levels decrease to
normal levels following appropriate therapy, and
thereby have the potential to become a treatment
efficacy marker. The reported elevations in
plasma suPAR levels during bacteraemia might
reflect up-regulation of uPAR on neutrophils,
monocytes and vascular cells, and indicate in-
creased neutrophile and monocyte activity. The
plasma suPAR level was elevated and was the
only independent predictor of mortality in
patients with pneumococcal bacteraemia. Hypo-
tension, renal failure, cerebral symptoms, CRP
and YKL-40 levels gave less or limited prognostic
information. Measurement of suPAR levels may
be useful for the clinical management of pneu-
mococcal bacteraemia.
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